You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 7 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 7 findings. Do not include any additional text.

Abstract:
ABSTRACT.BACKGROUND:: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety in the Phase 3 DEFINE and CONFIRM trials.

ABSTRACT.OBJECTIVE:: To evaluate delayed-release DMF in newly diagnosed relapsing–remitting multiple sclerosis (RRMS) patients, in a post-hoc analysis of integrated data from DEFINE and CONFIRM.

ABSTRACT.METHODS:: Patients included in the analysis were diagnosed with RRMS within 1 year prior to study entry and naive to MS disease-modifying therapy.

ABSTRACT.RESULTS:: The newly diagnosed population comprised 678 patients treated with placebo (n = 223) or delayed-release DMF 240 mg BID (n = 221) or TID (n = 234). At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo. In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo). Flushing and gastrointestinal events were associated with delayed-release DMF.

ABSTRACT.CONCLUSION:: Delayed-release DMF improved clinical and neuroradiological outcomes relative to placebo in newly diagnosed RRMS patients.

Findings:
[["delayed-release DMF 240 mg TID", "placebo", "mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)", "significantly decreased", "In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p \u003c 0.0001 versus placebo)."], ["delayed-release DMF 240 mg BID", "placebo", "annualized relapse rate - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)", "significantly decreased", "At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p \u003c 0.0001)"], ["delayed-release DMF 240 mg BID", "placebo", "annualized relapse rate - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)", "significantly decreased", "delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p \u003c 0.0001),"], ["delayed-release DMF 240 mg TID", "placebo", "annualized relapse rate - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)", "significantly decreased", "At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p \u003c 0.0001)"], ["delayed-release DMF 240 mg TID", "placebo", "annualized relapse rate - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)", "significantly decreased", "delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p \u003c 0.0001),"], ["delayed-release DMF 240 mg BID", "placebo", "risk of relapse - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)", "significantly decreased", "DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p \u003c 0.0001), risk of relapse by 54% and 57% (both p \u003c 0.0001)"], ["delayed-release DMF 240 mg BID", "placebo", "mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing\u2013remitting multiple sclerosis (RRMS)", "significantly decreased", "In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p \u003c 0.0001 versus placebo)."]]